The University of Southampton
University of Southampton Institutional Repository

Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system

Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
BACKGROUND: Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last decade. The objective of this study is to prepare a document providing recommendations for the use of SYSADOA in osteoarthritis (OA). METHODS: The following interventions were taken into consideration: avocado/soybean unsaponifiables, chondroitin sulfate, diacereine, glucosamine sulfate, hyaluronic acid, oral calcitonin, risedronate, strontium ranelate. Recommendations were based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. The GRADE system is based on a sequential assessment of the quality of evidence, followed by assessment of the balance between benefits versus downsides and subsequent judgment about the strength of recommendations. RESULTS: Chondroitin sulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronic acid have demonstrated pain reduction and physical function improvement with very low toxicity, with moderate to high quality evidence. Even if pre-clinical data and some preliminary in vivo studies have suggested that oral calcitonin and strontium ranelate could be of potential interest in OA, additional well-designed studies are needed. CONCLUSION: In the benefit/risk ratio, the use of chondroitin sulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronic acid could be of potential interest for the symptomatic management of OA
development, analogs & derivatives, health, thiophenes, antirheumatic agents, agent, osteoarthritis, glucosamine, methods, in-vivo, hyaluronic acid, public health, outcome assessment (health care), plant extracts, anthraquinones, calcitonin, system, toxicity, management, reduction, chondroitin sulfates, organometallic compounds, drug therapy, strength, clinical trials as topic, humans, administration & dosage, adverse effects, pain, acid, etidronic acid, statistics & numerical data
Bruyere, Olivier
78e7e880-9871-4463-af87-5bf2b11db696
Burlet, Nansa
ac700618-10d2-4a9c-8892-3727ab64c226
Delmas, Pierre D.
788d83fc-6eb8-41ac-a72b-d0c7c304db1f
Rizzoli, René
c1190577-8164-471d-b90f-6959f92bc25e
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Reginster, Jean-Yves
08b05e27-73dd-4ce9-90e5-d64ec922147a
Bruyere, Olivier
78e7e880-9871-4463-af87-5bf2b11db696
Burlet, Nansa
ac700618-10d2-4a9c-8892-3727ab64c226
Delmas, Pierre D.
788d83fc-6eb8-41ac-a72b-d0c7c304db1f
Rizzoli, René
c1190577-8164-471d-b90f-6959f92bc25e
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Reginster, Jean-Yves
08b05e27-73dd-4ce9-90e5-d64ec922147a

Bruyere, Olivier, Burlet, Nansa, Delmas, Pierre D., Rizzoli, René, Cooper, Cyrus and Reginster, Jean-Yves (2008) Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskeletal Disorders, 9 (165). (doi:10.1186/1471-2474-9-165).

Record type: Article

Abstract

BACKGROUND: Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last decade. The objective of this study is to prepare a document providing recommendations for the use of SYSADOA in osteoarthritis (OA). METHODS: The following interventions were taken into consideration: avocado/soybean unsaponifiables, chondroitin sulfate, diacereine, glucosamine sulfate, hyaluronic acid, oral calcitonin, risedronate, strontium ranelate. Recommendations were based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. The GRADE system is based on a sequential assessment of the quality of evidence, followed by assessment of the balance between benefits versus downsides and subsequent judgment about the strength of recommendations. RESULTS: Chondroitin sulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronic acid have demonstrated pain reduction and physical function improvement with very low toxicity, with moderate to high quality evidence. Even if pre-clinical data and some preliminary in vivo studies have suggested that oral calcitonin and strontium ranelate could be of potential interest in OA, additional well-designed studies are needed. CONCLUSION: In the benefit/risk ratio, the use of chondroitin sulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronic acid could be of potential interest for the symptomatic management of OA

PDF
1471-2474-9-165.pdf - Version of Record
Available under License Other.
Download (311kB)

More information

Published date: 2008
Keywords: development, analogs & derivatives, health, thiophenes, antirheumatic agents, agent, osteoarthritis, glucosamine, methods, in-vivo, hyaluronic acid, public health, outcome assessment (health care), plant extracts, anthraquinones, calcitonin, system, toxicity, management, reduction, chondroitin sulfates, organometallic compounds, drug therapy, strength, clinical trials as topic, humans, administration & dosage, adverse effects, pain, acid, etidronic acid, statistics & numerical data

Identifiers

Local EPrints ID: 70306
URI: https://eprints.soton.ac.uk/id/eprint/70306
PURE UUID: 3b5cedd9-fbd3-47d4-b7f3-2c03ab8b811f
ORCID for Cyrus Cooper: ORCID iD orcid.org/0000-0003-3510-0709

Catalogue record

Date deposited: 03 Feb 2010
Last modified: 06 Jun 2018 12:59

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×